A new opportunity exists in working with Chinese companies to establish scientific and business partnerships, and to create effective strategies. However, success in Asia will require changes in partnerships between Western and Asian companies.

Every company faces the question
“What should our China strategy be?”

This co-publication with the Society for Industrial Microbiology and Biotechnology and BioPlan Associates, Inc., provides an overview of the biopharmaceutical industry, and the state of technology in China.

Readers will be able to:
1. Assess the state of biopharmaceutical development in China
2. Understand general business practices
3. Analyze business opportunities and identify potential partners

A peer-reviewed, ready reference for all aspects of biopharmaceuticals in China, including an understanding of the China biopharma current situation, and future opportunities. Readers receive a comprehensive assessment of the state-of-the-industry, trends, and analysis. Information on all types of organizations involved in biopharma in China, whether they are domestic, multinational, or government.